fda approves first oral glp-1 obesity drug august 21 2025 Today the FDA issued its

In terms of immune modulation, GLP-1RAs demonstrate a bidirectional mechanism: they can enhance anti-tumor immune responses while modulating systemic inflammatory processes

Initially focused on managing type 2 diabetes, it would not be until 2014 that Novo Nordisks introduction of another GLP-1 agonist, Saxenda, marked a pivotal shift towards weight loss

If such benefits are confirmed in randomized trials, GLP-1 medications could support mental health care in addition to roles in weight management and glycaemic control

it enables you to build habits that support metabolic health independently

Both are the same medication with similar results

Additionally, allulose prevented liver triglyceride accumulation and promoted mitochondrial uncoupling in adipose tissue